Try our beta test site
23 studies found for:    "multiple endocrine neoplasia"
Show Display Options
RSS Create an RSS feed from your search for:
"multiple endocrine neoplasia"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Psychosocial Aspects of Multiple Endocrine Neoplasia (MEN) Syndromes
Condition: Multiple Endocrine Neoplasia
Intervention: Behavioral: Questionnaire
2 Recruiting Registry for Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2
Condition: Multiple Endocrine Neoplasia Syndromes
Intervention: Behavioral: Questionnaires
3 Completed Vancomycin Associated Red Man Syndrome (RMS)
Condition: Red Man Syndrome
Intervention:
4 Recruiting Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in MEN1 Patients
Condition: Multiple Endocrine Neoplasia
Intervention:
5 Recruiting Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)
Conditions: Multiple Endocrine Neoplasia;   Pancreatic Neuroendocrine Tumors;   Hyperparathyroidism
Interventions: Other: Genome Sequencing;   Other: Data Review
6 Completed Intravenous Immunoglobulin (IVIg) for the Treatment of Stiff-Man Syndrome (SMS)
Conditions: Muscle Rigidity;   Spasm;   Stiff Man Syndrome
Intervention: Drug: IVIg
7 Completed
Has Results
Treatment of Zollinger-Ellison Syndrome With Prevacid
Conditions: Zollinger-Ellison Syndrome;   Multiple Endocrine Neoplasia
Intervention: Drug: Lansoprazole (Prevacid)
8 Active, not recruiting Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
Conditions: Multiple Endocrine Neoplasia Type 1;   Pancreatic Neuroendocrine Carcinoma
Interventions: Radiation: Computed Tomography Perfusion Imaging;   Other: Laboratory Biomarker Analysis;   Biological: Ziv-Aflibercept
9 Completed Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients
Conditions: Medullary Thyroid Carcinoma;   Multiple Endocrine Neoplasia Type 2
Intervention:
10 Active, not recruiting Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
Conditions: Medullary Thyroid Carcinoma;   Multiple Endocrine Neoplasia Type 2A;   Multiple Endocrine Neoplasia Type 2B
Intervention: Drug: Vandetanib
11 Recruiting Studies of Inherited Diseases of Metabolism
Conditions: Hypercalcemia;   Hyperparathyroidism;   Multiple Endocrine Neoplasia
Intervention:
12 Active, not recruiting Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
Conditions: Multiple Endocrine Neoplasia;   Recurrent Thyroid Gland Carcinoma;   Thyroid Gland Medullary Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Sorafenib Tosylate
13 Not yet recruiting Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment
Condition: Pancreatic Neuroendocrine Tumors in MEN1
Intervention: Drug: Somatostatin-Analog
14 Not yet recruiting Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Conditions: Functional Pancreatic Neuroendocrine Tumor;   Malignant Somatostatinoma;   Merkel Cell Carcinoma;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Carcinoid Tumor;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2A;   Multiple Endocrine Neoplasia Type 2B;   Neuroendocrine Neoplasm;   Non-Functional Pancreatic Neuroendocrine Tumor;   Pancreatic Glucagonoma;   Pancreatic Insulinoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Adrenal Gland Pheochromocytoma;   Recurrent Merkel Cell Carcinoma;   Somatostatin-Producing Neuroendocrine Tumor;   Stage III Adrenal Cortex Carcinoma;   Stage III Thyroid Gland Medullary Carcinoma;   Stage IIIA Merkel Cell Carcinoma;   Stage IIIB Merkel Cell Carcinoma;   Stage IV Adrenal Cortex Carcinoma;   Stage IV Merkel Cell Carcinoma;   Stage IVA Thyroid Gland Medullary Carcinoma;   Stage IVB Thyroid Gland Medullary Carcinoma;   Stage IVC Thyroid Gland Medullary Carcinoma;   Thymic Carcinoid Tumor;   VIP-Producing Neuroendocrine Tumor;   Well Differentiated Adrenal Cortex Carcinoma;   Zollinger Ellison Syndrome
Interventions: Drug: Capecitabine;   Drug: Temozolomide;   Drug: Veliparib;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
15 Completed High Dose Somatostatin Analogues in Neuroendocrine Tumors
Conditions: Respiratory Tract Neoplasms;   Thymic Neoplasms;   Pancreatic Neoplasms;   Gastrointestinal Neoplasms;   Multiple Endocrine Neoplasia
Intervention: Drug: Octreotide-LAR
16 Recruiting Familial Investigations of Childhood Cancer Predisposition
Conditions: Acute Leukemia;   Adenomatous Polyposis;   Adrenocortical Carcinoma;   AML;   BAP1 Tumor Predisposition Syndrome;   Carney Complex;   Choroid Plexus Carcinoma;   Constitutional Mismatch Repair Deficiency Syndrome;   Diamond-Blackfan Anemia;   DICER1 Syndrome;   Dyskeratosis Congenita;   Emberger Syndrome;   Familial Acute Myeloid Leukaemia;   Familial Adenomatous Polyposis;   Fanconi Anemia;   Familial Cancer;   Familial Wilms Tumor;   Familial Neuroblastoma;   GIST;   Hereditary Breast and Ovarian Cancer;   Hereditary Paraganglioma-Pheochromocytoma Syndrome;   Hodgkin Lymphoma;   Juvenile Polyposis;   Li-Fraumeni Syndrome;   Lynch Syndrome;   MDS;   Melanoma Syndrome;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Neuroblastoma;   Neurofibromatosis Type 1;   Neurofibromatosis Type II;   Nevoid Basal Cell Carcinoma Syndrome;   Non Hodgkin Lymphoma;   Noonan Syndrome and Other Rasopathy;   Overgrowth Syndromes;   Pancreatic Cancer;   Peutz-Jeghers Syndrome;   Pheochromocytoma/Paraganglioma;   PTEN Hamartoma Tumor Syndrome;   Retinoblastoma;   Rhabdoid Tumor Predisposition Syndrome;   Rhabdomyosarcoma;   Rothmund-Thomson Syndrome;   Tuberous Sclerosis;   Von Hippel-Lindau Disease
Intervention:
17 Terminated
Has Results
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Conditions: Neuroendocrine Tumors;   Carcinoid Tumors;   Adrenal Gland Tumors;   Neuroblastoma;   Pancreatic Neuroendocrine Tumors;   Multiple Endocrine Neoplasia
Interventions: Drug: pertuzumab;   Drug: erlotinib
18 Completed
Has Results
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
Conditions: Gastrin-Producing Neuroendocrine Tumor;   Lung Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Tumor G1;   Multiple Endocrine Neoplasia Type 1;   Pancreatic Glucagonoma;   Pancreatic Insulinoma;   Pancreatic Polypeptide Tumor;   Recurrent Digestive System Neuroendocrine Tumor G1;   Recurrent Pancreatic Neuroendocrine Carcinoma;   Regional Digestive System Neuroendocrine Tumor G1;   Somatostatin-Producing Neuroendocrine Tumor
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Pazopanib Hydrochloride;   Other: Pharmacological Study
19 Recruiting Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors)
Conditions: Genetic Mutation;   MEN1
Interventions: Other: Chart Review;   Behavioral: Questionnaire
20 Unknown  Genetic Evaluation of Families With Endocrine Cancers
Conditions: Pancreatic Cancer;   Thymic Cancer;   Parathyroid Disease;   MEN1 Syndrome
Intervention: Genetic: Blood draw

   Previous Page Studies Shown (1-20) Next Page (21-23) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.